HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has upgraded Cidara Therapeutics (NASDAQ:CDTX) from Neutral to Buy, with a new price target of $24.
August 14, 2024 | 6:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has upgraded Cidara Therapeutics from Neutral to Buy, setting a new price target of $24.
The upgrade from Neutral to Buy and the new price target of $24 by HC Wainwright & Co. is likely to positively impact CDTX's stock price in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100